Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sympardi, Styliani
REACT, NCT06294600: Clarithromycin Treatment to Prevent Sepsis Progression in CAP	Recruiting	3	330	Europe	Clarithromycin 500mg, A β-lactam/β-lactamase inhibitor or a 3rd generation cephalosporin or a fluoroquinolone, Tablets	Hellenic Institute for the Study of Sepsis	Community-acquired Pneumonia	11/25	01/26
MODIFY, NCT05909683: Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the Trial)	Recruiting	3	190	Europe	Change of antimicrobials based on BCID2 and Reveal Rapid AST tests. Stop of antimicrobials based on PCT results., Standard of Care	Hellenic Institute for the Study of Sepsis	Sepsis	07/25	07/25
PRECISION, NCT05926505 / 2023-000102-25: Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome	Recruiting	2/3	182	Europe	Placebo, Anakinra 149 MG/ML Prefilled Syringe [Kineret]	Hellenic Institute for the Study of Sepsis, Hellenic Institute for the Study of Sepsis	Post-Acute COVID-19 Syndrome, Post-Acute COVID-19, Long COVID	08/25	08/25